stock-detail (PIRS)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 06:18 pm

4/24/2017 06:18 pm

4/24/2017 06:18 pm

4/24/2017 06:18 pm

4/24/2017 06:18 pm

Pieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate Update

3/23/2017 12:01 am

[Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today reported ...

Pieris Pharmaceuticals to Host Full-Year 2016 Investor Call And Corporate Update on March 23, 2017

3/15/2017 11:03 am

[Marketwired] - Pieris Pharmaceuticals, Inc. , a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, will host a Full-Year 2016 Investor Call on Thursday, March 23, 2017 at 10:00 AM ...

Pieris Pharmaceuticals to Present at Oppenheimer's 27th Annual Healthcare Conference, Wednesday, March 22nd at 11:30 am EDT

3/14/2017 11:03 am

[Marketwired] - Pieris Pharmaceuticals, Inc. , a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will present a corporate overview ...

Pieris Pharmaceuticals to Present at the 29th Annual Roth Conference Monday, March 13th at 2:00 pm PST

3/7/2017 12:03 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will present a corporate overview ...

Pieris Pharmaceuticals Announces Presentation of IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2017 Meeting of the American Association for Cancer Research (AACR)

3/6/2017 12:03 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced today that a set of ex vivo and in ...

Pieris Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6th at 4:40 pm EST

3/1/2017 01:00 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will present a corporate overview ...

Pieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA Pharmaceutical

2/27/2017 12:03 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, today announced that it has granted ASKA Pharmaceutical ...

Pieris Pharmaceuticals to Present at the Bio CEO Investor Conference on February 13th at 1:30 pm EST

2/8/2017 12:03 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will present a corporate overview ...

Pieris Announces Management Transition

2/7/2017 10:02 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, today announced that Darlene Deptula-Hicks ...

Pieris Pharmaceuticals to Host Investor Call Today to Discuss Servier Collaboration

1/5/2017 12:03 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced it ...

Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance

1/5/2017 12:00 pm

[Marketwired] - Pieris and Servier, an independent international pharmaceutical company headquartered in France with annual sales of more than EUR4 billion, to jointly pursue several bispecific therapeutic programs including ...